The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma : The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)‎

Abstract EN

Background.

The individual concerns of non-Hodgkin’s lymphoma (NHL) patients require identification and assessment during clinical research proposing to measure patients’ outcomes.

The FACT-Lym was developed as part of the FACIT measurement system to address health-related quality-of-life (HRQL) issues for NHL patients.

Patients and Methods.

Items for the FACT lymphoma subscale (LymS) were generated from healthcare provider interviews, published literature, and content validity patient interviews.

The FACT-Lym was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3).

Results.

Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item LymS to 15 items.

The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment.

Internal consistency coefficients for the 15-item LymS (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability.

Correlations between LymS and SF-36 physical (r=.62) and mental (r=.48) summary scores reflect concurrent validity.

Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores.

The FACT-LymS differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse), P<0.001.

Conclusions.

These results support the validity of the FACT-Lym and suggest it will be a useful targeted endpoint in NHL clinical research.